Endo and Jubilant Expand Oncology Discovery Partnership on Successful Delivery of Early Milestone
The year-old partnership focuses on Jubilant delivering preclinicalcandidates in the therapeutic area of oncology. Endo owns the late-stagedevelopment and commercialization rights for molecules discovered in thepartnership. Jubilant derives research funding and success-based developmentand commercialization milestones.
Commenting on this development, Sri Mosur, CEO & President, Global DrugDiscovery & Development said: "We are pleased that we could deliver earlysuccess to the discovery portfolio efforts at Endo Pharmaceuticals and thisexpansion is a testimony to Jubilant's focus in building world class oncologycapabilities, among other therapeutic areas. This collaboration furtherreinforces the concept of globally leveraged R&D that creates a platform forscientists from Endo and Jubilant to collaborate in finding affordableremedies for cancer patients worldwide."
"We have been impressed by the quality of the science and the progressmade to date by the Jubilant team on our ongoing oncology discovery program,said Dr. Ivan Gergel, M.D, Executive Vice President of R&D at EndoPharmaceuticals. "Expanding our relationship in this important therapeuticarea is consistent with our strategy of building Endo's pipeline using avirtual discovery approach, in conjunction with our in-licensing efforts."
About Jubilant Biosys
Jubilant Biosys Ltd. (JBL) (www.jubilantbiosys.com), a subsidiary ofJubilant Organosys Ltd., provides integrated drug discovery and developmentsolutions to the global pharmaceutical industry. Jubilant Biosys has anintegrated state of the art facility in Bangalore. The Center houses over 450scientists specializing in multiple disciplines to include Discovery biology,medicinal chemistry, structural biology, pharmacology, toxicology, pharmachem, molecular modeling, crystallography and information technologysupporting discovery efforts.
About Jubilant Organosys Limited
Jubilant Organosys Ltd., headquartered at Noida, an integratedpharmaceutical industry player, is India's largest Custom Research andManufacturing Services company (CRAMS) and a leading Drug Discovery andDevelopment Solution Provider. The company has a presence across thepharmaceutical value chain for providing products and services such asproprietary products, exclusive synthesis, active pharmaceutical ingredients,contract manufacturing of sterile injectables & non-steriles products,radiopharmaceuticals, generic dosage forms, drug discovery services,medicinal chemistry services, clinical research services, and Health Care.The Company also manufactures Industrial and Performance products.http://www.jubl.com
Statements in this document relating to future status, events, orcircumstances, including but not limited to statements about plans andobjectives, the progress and results of research and development, potentialproduct characteristics and uses, product sales potential and target datesfor product launch are forward-looking statements based on estimates and theanticipated effects of future events on current and developing circumstances.Such statements are subject to numerous risks and uncertainties and are notnecessarily predictive of future results. Actual results may differmaterially from those anticipated in the forward-looking statements. JubilantOrganosys may, from time to time, make additional written and oral forwardlooking statements, including statements contained in the Company's filingswith the regulatory bodies and its reports to shareholders. The Companyassumes no obligation to update forward-looking statements to reflect actualresults, changed assumptions or other factors.For Business Queries Kailash Swarna Sr. VP and COO, Jubilant Drug Discovery and Development firstname.lastname@example.org For Media Seema Ahuja VP-Corporate Marketing & Communications Jubilant Organosys Ltd +919810631779, email@example.com
SOURCE Jubilant Biosys Ltd
You May Also Like